Member Info for borrowfundsfrommummy

Thought Goliath were meant to be taking these out next month… well done if can catch it before its rise

One is US version . I was previously only in that as rises a lot faster. As far as I could tell all their bitcoin stuff was old and they were being forced into a hostile takeover.. maybe it’s a death rise or not going ahead. Goliath was the private buyer in the states

Took some on Amoi .. bottom zone around 0.86p in my opinion.. far too quiet recently but it can rocket on small trades.. if they buy bitcoin again like before then a quick bagger there

Think bottom is in now. If AMOI can buy some more Bitcoin as it seems to be in fashion again, think their will be a big rise again

Arb flying now… US version done well too… not kept up to date with it recently but thought they were forced into selling due to being skint

1.10p paid break out time

How is arb still climbing . They were due to be sold in November?? Taken a punt on Tir .. Bitcoin movement on it seems

Taken a few .. looks ready to love northwards

Same , revenue of 3.5million and reinvestments are too good to be sniffed at. Spread ex definitely the pain here but once they are out then should be all guns blazing for end of year site completion. Add whilst it’s cheap

Bitcoin and treasury investing also will attract investors if the company continue to do it. Having seen Bmv and Amoi recently they did not continue to do this loosing interest in the process.. definitely one to watch for news updates

Have had Wcat and ukog in investments before but both always turn out to be damp squibs .. not sure what the investment case in either but perhaps to multibag there is none.

Aeg looking for a mast style rise there . John Story owns 29% so free float reduced . Dropped on news but feel big riser in next couple of months

Genf big trades there last week .. placing pre sold or something. 40 million trade

Early sellers on news . With John Story owning 29% takes out a nice chunk of free float. Looking for a mast style rise here over next couple of months

Nice RNS on Aeg.. big mover soon perhaps

Took some in the bell. Agreed great potential here

6

expanded access to gallium maltolate (gam) - end brain cancer

gallium maltolate is an orally available drug that uses the element gallium to treat conditions like cancer and some infectious diseases by interfering with iron metabolism. because gallium acts as a "trojan horse," mimicking iron to enter cells, it blocks essential iron-dependent enzymes, including those needed for dna synthesis, which halts cell growth and can lead to cell death. it also possesses anti-inflammatory and antibacterial properties.

vivian therapeutics offer personalised cancer treatments by engineering patients tumour mutations into fruit fly avatars to screen drug ****tails creating personalised treatment recommendations through their tumatch software and supporting bio pharma partners in drug discovery for cancer and other genetic diseases..

bit of cut and pasting but the general info is there

gallium multilateral also used for arthritis, psoriasis etc under the skin cream company gallixa (partners of ibai)

about vivian therapeutics

quite lengthy but very interesting

5

home — vividion therapeutics

vivan therapeutics develops personalized cancer treatments and therapeutic recommendations for patients and supports biopharmaceutical companies in drug discovery. their technology, the personal discovery process (pdp), involves creating fruit fly models with a patient's tumor genetics to screen large numbers of drug ****tails and identify effective treatments. vivan also offers tumatch, an ai-powered software for rapid, personalized clinical decision support.

for patients

personalized treatment:

vivan therapeutics provides personalized treatment recommendations by matching a patient's tumor genetics to effective therapies.

tumatch service:

this software uses ai and a large database to suggest new, personalized drug combinations for individual patients.

second opinions & concierge services:

vivan offers support services to patients and their oncologists, helping them navigate treatment options, particularly for complex or hard-to-treat cancers.

for biopharma partners

drug discovery:

vivan therapeutics uses its high-throughput drug screening platform in fruit fly models to test investigational drugs and discover new drug combination therapies.

patient stratification:

their technology enables patient stratification and precision-driven clinical trial design by tailoring treatments to specific genetic signatures.

drug repurposing:

the platform helps identify novel uses for existing drugs and can also aid in rescuing failed drug candidates.

From Phillip Howdle

IBAI has received two Rare Pediatric Disease (RPD) designations. A PRV is awarded upon final FDA approval of the drug. The average sale value for a voucher in 2020-2024 was $107m. In 2025, this surged to $150m.

Hard enough to buy let alone sell… yes next week will be interesting for sure. Viva Therapeutics very interesting partnership… see where today ends

Few sellers out early but it’s a decent cancer RNS .. few bags next week perhaps IBAI

Bouncing a bit but think it will rise this afternoon.. big news

Big RNS on Ibai flying already